AGITG Trial News
AGITG Trial news: The AGITG currently has fourteen studies open to recruitment and three studies in... Read More
AGITG Trial Updates: August 2020
ASCOLT Low-dose aspirin could play an important role in reducing the recurrence of colorectal cancer. The ASCOLT study is an international phase III trial that aims to discover whether taking a daily 200mg dose of aspirin for three years could help to prevent colorectal cancer returning in people who have already... Read More
Member Spotlight: Associate Professor Jeanne Tie
Associate Professor Jeanne Tie is a medical oncology staff specialist at the Peter MacCallum Cancer Centre and the... Read More
Introducing the Patient Central Hub
Many healthcare professionals and patient organisations in Australia develop projects leading to better care for cancer patients and improving quality of life for these people. Unfortunately, these projects are often only implemented at the institution where the initiative was developed. All cancer patients in Australia should enjoy the benefits of these... Read More
Member Spotlight: Professor Steve Ackland
Professor Steve Ackland is a Medical Oncologist based in Newcastle, Director of Hunter Cancer Research Alliance, and Editor-in-Chief... Read More
June 2020: Trial Updates
NABNEC The NABNEC study for patients with advanced gastrointestinal neuroendocrine carcinomas (NECs) is currently open in 16 sites across all six states in Australia. The aim of NABNEC is to determine the safety and efficacy of carboplatin plus nab-paclitaxel in comparison to the current standard chemotherapy plan (carboplatin plus etoposide) and find... Read More
Welcome to Dr Lorraine Chantrill, new AGITG Chair
On 15 May 2020, the AGITG welcomed Dr Lorraine Chantrill as the new Chair of the organisation. Dr... Read More
Group Coordinator trial update May 2020
While many of us have been working from home, there has certainly been a lot of work to... Read More
May 2020: AGITG Trial Updates
SSGXXII approved by the Upper GI Working Party The SSGXXII trial concept was approved by the Upper GI Working... Read More
COVID-19 April update
As the COVID-19 pandemic continues to evolve, we are also continuing to evolve the way we work –... Read More
Welcoming Erin Burgess as Communications Manager
Erin recently joined the AGITG and GI Cancer Institute as Communications Manager. How did you come to work in... Read More
April 2020: AGITG Trial Updates
DYNAMIC-Pancreas DYNAMIC-Pancreas is one of three AGITG trials investigating ctDNA analysis, an emerging area in GI oncology that shows... Read More
March 2020: Colorectal cancer trial updates
Final patient joins MODULATE The final patient participating in the MODULATE clinical trial has now joined, meaning that all... Read More
COVID-19 member update
We want to reassure you that we are taking the COVID-19 situation very seriously. The health and safety... Read More
The 2020 AGITG Idea Generation Workshop
AGITG is hosting another Workshop in late 2020 in Sydney. Following the member survey for the 2020 research priorities,... Read More
February 2020: Trial Updates
Recent Sites Activated The following sites have opened for AGITG trials in the past month: Read More
Cancer Symptom Trials Annual Research Forum
This report was provided by Associate Professor Richard de Abreu Lourenco from the Centre for Health Economics Research... Read More
An update from ASCO GI
AGITG presentations Two AGITG trials were selected for presentation. The MONARCC trial was presented at the Trials in... Read More
AGITG Trial Updates December 2019
NEO-CREATE becomes the second AGITG Endorsed Study The pilot study NEO-CREATE has become the second AGITG... Read More
MODULATE reaches over 75% of its recruitment target
The MODULATE study, led by Prof Niall Tebbutt, is investigating the effectiveness, safety and tolerability of nivolumab with... Read More